AR124651A1 - Vectores de aav dirigidos a linfocitos t - Google Patents
Vectores de aav dirigidos a linfocitos tInfo
- Publication number
- AR124651A1 AR124651A1 ARP220100072A ARP220100072A AR124651A1 AR 124651 A1 AR124651 A1 AR 124651A1 AR P220100072 A ARP220100072 A AR P220100072A AR P220100072 A ARP220100072 A AR P220100072A AR 124651 A1 AR124651 A1 AR 124651A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- capsid protein
- transduction
- aav
- sequence
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 5
- 108090000565 Capsid Proteins Proteins 0.000 abstract 8
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 8
- 230000026683 transduction Effects 0.000 abstract 5
- 238000010361 transduction Methods 0.000 abstract 5
- 241000700605 Viruses Species 0.000 abstract 4
- 210000000234 capsid Anatomy 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000013607 AAV vector Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La descripción proporciona proteínas de la cápside de AAV variantes y cápsides de AAV y vectores de virus que las comprenden. Los vectores de virus descritos en la presente pueden tener una mayor transducción en una célula diana de interés, tal como un linfocito T, en comparación con las secuencias de la cápside de AAV naturales. La descripción también proporciona métodos para administrar los vectores de virus y las cápsides de virus de la descripción a una célula o a un paciente que lo necesita. Reivindicación 1: Un vector de virus adenoasociado recombinante (AAV) que comprende una proteína de la cápside, en donde la proteína de la cápside comprende un péptido asociado a la transducción que tiene la secuencia de cualquiera de las SEQ ID Nº 17 a 23. Reivindicación 5: Un vector de AAV recombinante que comprende una proteína de la cápside, en donde la proteína de la cápside comprende la secuencia de la SEQ ID Nº 1, en donde los aminoácidos 454 - 460 de la SEQ ID Nº 1 se reemplazan con un péptido asociado a la transducción que comprende la secuencia X1-X2-X3-X4-X5-X6-X7 (SEQ ID Nº 24). Reivindicación 24: Un vector de AAV recombinante que comprende una proteína de la cápside, en donde la proteína de la cápside comprende un péptido asociado a la transducción que tiene una secuencia de aminoácidos de la SEQ ID Nº 16, en donde el péptido asociado a la transducción reemplaza los aminoácidos 454 - 460 con respecto a la SEQ ID Nº 1. Reivindicación 26: Un ácido nucleico que codifica una proteína de la cápside de AAV recombinante que tiene la secuencia de cualquiera de las SEQ ID Nº 2, 4, 6, 8, 10, 12 y 14.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163137497P | 2021-01-14 | 2021-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124651A1 true AR124651A1 (es) | 2023-04-19 |
Family
ID=81328090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100072A AR124651A1 (es) | 2021-01-14 | 2022-01-14 | Vectores de aav dirigidos a linfocitos t |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240123085A1 (es) |
| EP (1) | EP4277920A1 (es) |
| JP (1) | JP2024503091A (es) |
| KR (1) | KR20230135093A (es) |
| CN (1) | CN117203222A (es) |
| AR (1) | AR124651A1 (es) |
| AU (1) | AU2022208037A1 (es) |
| CA (1) | CA3204794A1 (es) |
| TW (1) | TW202242124A (es) |
| WO (1) | WO2022155482A1 (es) |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988002026A1 (en) | 1986-09-08 | 1988-03-24 | Applied Biotechnology, Inc. | Empty viral capsid vaccines |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| WO1990005142A1 (en) | 1988-11-10 | 1990-05-17 | Imperial Cancer Research Technology Ltd. | Polypeptides |
| US5916563A (en) | 1988-11-14 | 1999-06-29 | United States Of America | Parvovirus protein presenting capsids |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| ES2026826A6 (es) | 1991-03-26 | 1992-05-01 | Ercros Sa | Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados. |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| ES2279531T3 (es) | 1995-12-15 | 2007-08-16 | Intronn, Inc. | Moleculas terapeuticas generadas por corte y empalme en trans. |
| US6083702A (en) | 1995-12-15 | 2000-07-04 | Intronn Holdings Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| US20030215422A1 (en) | 1996-09-11 | 2003-11-20 | John A. Chiorini | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| JP4060531B2 (ja) | 1998-05-28 | 2008-03-12 | アメリカ合衆国 | Ａａｖ５ベクターおよびその使用 |
| AU774706B2 (en) | 1998-09-22 | 2004-07-08 | Johns Hopkins University, The | Methods for large-scale production of recombinant AAV vectors |
| CA2349838C (en) | 1998-11-05 | 2011-06-07 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
| US7314912B1 (en) | 1999-06-21 | 2008-01-01 | Medigene Aktiengesellschaft | AAv scleroprotein, production and use thereof |
| DE60117550T2 (de) | 2000-06-01 | 2006-12-07 | University Of North Carolina At Chapel Hill | Doppelsträngige parvovirus-vektoren |
| DE60139471D1 (de) | 2000-06-01 | 2009-09-17 | Univ North Carolina | Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren |
| US6623729B2 (en) | 2001-07-09 | 2003-09-23 | Korea Advanced Institute Of Science And Technology | Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer |
| AU2003223766A1 (en) | 2002-04-30 | 2003-11-17 | University Of North Carolina At Chapel Hill | Secretion signal vectors |
| ITRM20020253A1 (it) | 2002-05-08 | 2003-11-10 | Univ Roma | Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche. |
| FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
| JP4346526B2 (ja) | 2004-08-31 | 2009-10-21 | 株式会社東芝 | 半導体集積回路装置 |
| WO2006029319A2 (en) | 2004-09-09 | 2006-03-16 | The General Hospital Corporation | Modulating phosphatase activity in cardiac cells |
| CN101124328A (zh) | 2004-12-15 | 2008-02-13 | 北卡罗来纳查佩尔山大学 | 嵌合载体 |
| CN101213203A (zh) | 2005-04-29 | 2008-07-02 | 教堂山北卡罗莱纳州大学 | 在转录后水平调节核酸表达的方法和组合物 |
| WO2006119432A2 (en) * | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| CN101437833A (zh) | 2006-02-10 | 2009-05-20 | 辛辛那提大学 | 作为心脏功能调节剂的磷酸酶抑制剂蛋白-1 |
| US7892824B2 (en) | 2007-01-18 | 2011-02-22 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nNOS to the sarcolemma |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| EP3838297A1 (en) | 2013-03-15 | 2021-06-23 | The University of North Carolina at Chapel Hill | Methods and compositions for dual glycan binding aav vectors |
| CN109923211A (zh) * | 2016-09-08 | 2019-06-21 | 蓝鸟生物公司 | Pd-1归巢核酸内切酶变体、组合物及使用方法 |
| WO2019195449A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| CN112533644A (zh) | 2018-04-03 | 2021-03-19 | 斯特里迪比奥公司 | 靶向眼组织的病毒载体 |
| MX2020010466A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus que evitan anticuerpos. |
-
2022
- 2022-01-13 TW TW111101402A patent/TW202242124A/zh unknown
- 2022-01-14 AR ARP220100072A patent/AR124651A1/es unknown
- 2022-01-14 JP JP2023542960A patent/JP2024503091A/ja active Pending
- 2022-01-14 CA CA3204794A patent/CA3204794A1/en active Pending
- 2022-01-14 WO PCT/US2022/012542 patent/WO2022155482A1/en active Application Filing
- 2022-01-14 CN CN202280016202.8A patent/CN117203222A/zh active Pending
- 2022-01-14 AU AU2022208037A patent/AU2022208037A1/en active Pending
- 2022-01-14 KR KR1020237026711A patent/KR20230135093A/ko unknown
- 2022-01-14 EP EP22703750.4A patent/EP4277920A1/en active Pending
-
2023
- 2023-07-12 US US18/221,211 patent/US20240123085A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022155482A1 (en) | 2022-07-21 |
| WO2022155482A9 (en) | 2022-12-22 |
| TW202242124A (zh) | 2022-11-01 |
| KR20230135093A (ko) | 2023-09-22 |
| CA3204794A1 (en) | 2022-07-21 |
| AU2022208037A1 (en) | 2023-07-20 |
| EP4277920A1 (en) | 2023-11-22 |
| US20240123085A1 (en) | 2024-04-18 |
| CN117203222A (zh) | 2023-12-08 |
| JP2024503091A (ja) | 2024-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003757A1 (es) | Vectores de aav que tienen una desamidación reducida de la cápside y sus usos (divisional solic 202002200). | |
| MX2021011468A (es) | Vectores de virus adenoasociados recombinantes. | |
| MX2020008932A (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. | |
| MX2019010275A (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este. | |
| JP2023179436A5 (es) | ||
| AR080229A1 (es) | Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23) | |
| AR109196A1 (es) | Métodos y composiciones para la expresión génica en plantas | |
| RU2003106809A (ru) | Гены гомологичных иммунодоминантных белков ehrlichia canis в 28-килодальтон и их применение | |
| MX2020010464A (es) | Vectores de virus que evitan anticuerpos. | |
| CO2021016198A2 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
| PE20220429A1 (es) | Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| AR125406A1 (es) | Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen | |
| PE20221254A1 (es) | Proteina vp1 modificada aislada de la capside del virus adeno-asociado de serotipo 5 (aav5), capside y vector basado en la misma | |
| AR125191A1 (es) | Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso | |
| AR124651A1 (es) | Vectores de aav dirigidos a linfocitos t | |
| AR123189A1 (es) | VACUNA DE SINUCLEÍNA a PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS | |
| CO2023015564A2 (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv | |
| AR122404A1 (es) | Variantes de cápside y usos de las mismas | |
| EA202092065A1 (ru) | ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA) | |
| AR124216A1 (es) | Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen | |
| CO2022004535A2 (es) | Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes | |
| AR128450A1 (es) | Vectores de virus adeno-asociados recombinantes, y métodos de uso de los mismos | |
| AR124143A1 (es) | Método para tratar la distrofia muscular mediante el direccionamiento al gen dmpk | |
| AR127206A1 (es) | Cápsides de aav novedosas y composiciones que las contienen |